What are Marc Hedrick’s PLUS THERAPEUTICS share holdings after this Form 4?

After the reported transactions, Marc H. Hedrick directly holds 34,431 shares of PLUS THERAPEUTICS Common Stock. He also holds 163,650 Restricted Stock Units, each representing a contingent right to receive one additional share of Common Stock in the future.

Is the PSTV CEO’s Form 4 transaction an open-market purchase or compensation-related?

The transaction is compensation-related, not an open-market purchase. The Form 4 shows an exercise or conversion of Restricted Stock Units into Common Stock at a $0.00 exercise price, reflecting scheduled vesting of prior equity awards.

Plus Therapeutics (PSTV) CEO gains 16,439 shares from RSU vesting

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

PLUS THERAPEUTICS, INC. Chief Executive Officer Marc H. Hedrick reported routine equity compensation activity as Restricted Stock Units vested into Common Stock. On July 1, 2026, RSU vesting resulted in the acquisition of 16,439 shares of Common Stock at an exercise price of $0.00 per share. Following these conversions, he directly holds 34,431 shares of Common Stock and 163,650 RSUs, which represent contingent rights to receive an equal number of shares. The RSU grants vest in twelve substantially equal quarterly installments beginning on October 1, 2025, April 1, 2026, and July 1, 2026.

Insider Trade Summary

16,439 shares exercised/converted

Mixed 6 txns

Insider HEDRICK MARC H

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	6,387	$0.00	--
Exercise	Restricted Stock Units	8,066	$0.00	--
Exercise	Restricted Stock Units	1,986	$0.00	--
Exercise	Common Stock	6,387	$0.00	--
Exercise	Common Stock	8,066	$0.00	--
Exercise	Common Stock	1,986	$0.00	--

Holdings After Transaction: Restricted Stock Units — 163,650 shares (Direct, null); Common Stock — 34,431 shares (Direct, null)

Footnotes (1)

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

Key Figures

Shares acquired via RSU vesting: 16,439 shares Common Stock holdings after transactions: 34,431 shares RSUs remaining after transactions: 163,650 units +1 more

4 metrics

Shares acquired via RSU vesting 16,439 shares Common Stock acquired on July 1, 2026 from RSU conversions

Common Stock holdings after transactions 34,431 shares Directly held by CEO following July 1, 2026 conversions

RSUs remaining after transactions 163,650 units Restricted Stock Units held, each for one share of Common Stock

Exercise price of RSU conversions $0.00 per share Price at which RSUs converted into Common Stock

Key Terms

Restricted Stock Unit ("RSU"), contingent right, quarterly installments

3 terms

Restricted Stock Unit ("RSU") financial

"Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share"

contingent right financial

"represents a contingent right to receive one share of the issuer's Common Stock"

quarterly installments financial

"vesting of an RSU grant which occurs in twelve substantially equal quarterly installments"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/01/2026 - 01:31 PM Accepted by SEC EDGAR 07/01/2026 - 01:30 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HEDRICK MARC H

(Last)

(First)

(Middle)

C/O PLUS THERAPEUTICS INC.

6420 LEVIT GREEN BOULEVARD, SUITE 310

(Street)

HOUSTON

TEXAS

77021

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLUS THERAPEUTICS, INC. [ PSTV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/01/2026		M		6,387⁽²⁾	A	$0⁽¹⁾	34,431	D
Common Stock	07/01/2026		M		8,066⁽³⁾	A	$0⁽¹⁾	42,497	D
Common Stock	07/01/2026		M		1,986⁽⁴⁾	A	$0⁽¹⁾	44,483	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0	07/01/2026		M			6,387	⁽²⁾	⁽²⁾	Common Stock	6,387	$0	163,650	D
Restricted Stock Units	$0	07/01/2026		M			8,066	⁽³⁾	⁽³⁾	Common Stock	8,066	$0	155,584	D
Restricted Stock Units	$0	07/01/2026		M			1,986	⁽⁴⁾	⁽⁴⁾	Common Stock	1,986	$0	153,598	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the issuer's Common Stock.

2. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on October 1, 2025.

3. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on April 1, 2026.

4. Represents the vesting of an RSU grant which occurs in twelve substantially equal quarterly installments beginning on July 1, 2026.

	Andrew Sims, as attorney-in-fact	07/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did PSTV CEO Marc Hedrick report on this Form 4?

Marc H. Hedrick reported RSU vesting that converted into Common Stock. On July 1, 2026, Restricted Stock Units settled into 16,439 shares at a $0.00 exercise price as part of his equity compensation, increasing his directly held shares.

How many PLUS THERAPEUTICS (PSTV) shares did the CEO acquire through RSU vesting?

The CEO acquired 16,439 shares of PLUS THERAPEUTICS Common Stock through RSU vesting. These shares came from three RSU tranches converting into stock on July 1, 2026, at an exercise price of $0.00 per share.

How do the PLUS THERAPEUTICS RSUs reported by the CEO vest over time?

The RSUs vest in twelve substantially equal quarterly installments. One grant begins vesting on October 1, 2025, another on April 1, 2026, and another on July 1, 2026, leading to periodic conversions of RSUs into Common Stock as they vest.